510(k) Report

510(k) · Cleared

Cleared

VITEK 2 AST-GN Cefepime (<=0.12->=32 ug/mL)

K161227510(k) TraditionalCleared Jul 20, 201679-day reviewClass II21 CFR 866.1645

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

bioMerieux, Inc. · LON System, Test, Automated, Antimicrobial Susceptibility, Short Incubation

Cleared on Jul 20, 2016 as substantially equivalent to K121546 (bioMerieux, Inc., 2012) after a 79-day review. Its family tree reaches back 7 generations to 2003. 5 later devices descend from it.

Decided
Jul 20, 2016
Review
79 days
Class
Class II
Product code
LON
Recalls
None
Predicates
1

Its longest line of descent runs back 7 generations to K032788 (2003). 5 later devices descend from it, 2 citing it directly.

Descendants, by year cleared 2017: 2 descendants cleared2019: 1 descendant cleared2020: 1 descendant cleared2021: 1 descendant clearedK032788 · Vitek 2 Gram Negative Gatifloxacin · bioMerieux, Inc. · 2003K041982 · Vitek 2 Gram Negative Ertapenem · bioMerieux, Inc. · 2004 · recalledK072038 · Vitek 2 Gram Negative Levofloxacin · bioMerieux, Inc. · 2007K082346 · Vitek 2 Gram Negative Doripenem · bioMerieux, Inc. · 2009K091899 · Vitek 2 Gram Negative Meropenem · bioMerieux, Inc. · 2009K103752 · Vitek 2 Systems (PC) 5.02 Software · bioMerieux, Inc. · 2011K121546 · Vitek 2 Gram Negative Doxycycline · bioMerieux, Inc. · 2012200020052010201520202025
Descendants, by generation 1 generation forward: 2 descendants2 generations forward: 1 descendant3 generations forward: 1 descendant4 generations forward: 1 descendant K121546 · Vitek 2 Gram Negative Doxycycline · bioMerieux, Inc. · 2012K103752 · Vitek 2 Systems (PC) 5.02 Software · bioMerieux, Inc. · 2011K091899 · Vitek 2 Gram Negative Meropenem · bioMerieux, Inc. · 2009K082346 · Vitek 2 Gram Negative Doripenem · bioMerieux, Inc. · 2009K072038 · Vitek 2 Gram Negative Levofloxacin · bioMerieux, Inc. · 2007K041982 · Vitek 2 Gram Negative Ertapenem · bioMerieux, Inc. · 2004 · recalledK032788 · Vitek 2 Gram Negative Gatifloxacin · bioMerieux, Inc. · 2003−50
  1. Root · 7 generations backK032788 Vitek 2 Gram Negative GatifloxacinbioMerieux, Inc. · 2003
  2. 6 generations backK041982 Vitek 2 Gram Negative ErtapenembioMerieux, Inc. · 2004 · Recalled
  3. 5 generations backK072038 Vitek 2 Gram Negative LevofloxacinbioMerieux, Inc. · 2007
  4. 4 generations backK082346 Vitek 2 Gram Negative DoripenembioMerieux, Inc. · 2009
  5. 3 generations backK091899 Vitek 2 Gram Negative MeropenembioMerieux, Inc. · 2009
  6. 2 generations backK103752 Vitek 2 Systems (PC) 5.02 SoftwarebioMerieux, Inc. · 2011
  7. 1 generation backK121546 Vitek 2 Gram Negative DoxycyclinebioMerieux, Inc. · 2012
  8. This deviceK161227 VITEK 2 AST-GN Cefepime (<=0.12->=32 ug/mL)bioMerieux, Inc. · 2016
  9. Descendant · cites it directly · 3 of its ownK172731 VITEK 2 AST-GN Amikacin (<=1 ->=64 ug/mL)bioMerieux, Inc. · 2017
  10. Descendant · 2 generations on · 2 of its ownK183415 VITEK 2 AST-Gram Negative Imipenem (</=0.25->= 16 ug/mL)bioMerieux, Inc. · 2019 · Recalled
  11. Descendant · 3 generations on · 1 of its ownK193572 VITEK 2 AST-Gram Negative Imipenem/Relebactam (<=0.25/4 - >=16/4…bioMerieux, Inc. · 2020
  12. Descendant · 4 generations on · 0 of its ownK211136 VITEK 2 AST-Gram Negative Imipenem/Relebactam (<0.25/4 - >16/4 ug/ML)bioMerieux, Inc. · 2021 · Recalled
  13. Descendant · cites it directly · 0 of its ownK163006 VITEK 2 AST-GN Tigecycline (<0.5->8 ug/mL)bioMerieux, Inc. · 2017

Most influential descendants

Showing 5 of 5 · See all
  • K172731VITEK 2 AST-GN Amikacin (<=1 ->=64 ug/mL)bioMerieux, Inc. · 2017 · cites it directly3descendants
  • K183415VITEK 2 AST-Gram Negative Imipenem (</=0.25->= 16 ug/mL)bioMerieux, Inc. · 2019 · 2 generations on2descendants
  • K193572VITEK 2 AST-Gram Negative Imipenem/Relebactam (<=0.25/4 - >=16/4 µg/mL)bioMerieux, Inc. · 2020 · 3 generations on1descendant
  • K211136VITEK 2 AST-Gram Negative Imipenem/Relebactam (<0.25/4 - >16/4 ug/ML)bioMerieux, Inc. · 2021 · 4 generations on0descendants
  • K163006VITEK 2 AST-GN Tigecycline (<0.5->8 ug/mL)bioMerieux, Inc. · 2017 · cites it directly0descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−7K032788Vitek 2 Gram Negative GatifloxacinbioMerieux, Inc.2003—
−6K041982Vitek 2 Gram Negative ErtapenembioMerieux, Inc.20041
−5K072038Vitek 2 Gram Negative LevofloxacinbioMerieux, Inc.2007—
−4K082346Vitek 2 Gram Negative DoripenembioMerieux, Inc.2009—
−3K091899Vitek 2 Gram Negative MeropenembioMerieux, Inc.2009—
−2K103752Vitek 2 Systems (PC) 5.02 SoftwarebioMerieux, Inc.2011—
−1K121546Vitek 2 Gram Negative DoxycyclinebioMerieux, Inc.2012—
0 (this device)K161227VITEK 2 AST-GN Cefepime (<=0.12->=32 ug/mL)bioMerieux, Inc.2016—
+1K172731VITEK 2 AST-GN Amikacin (<=1 ->=64 ug/mL)bioMerieux, Inc.2017—
+2K183415VITEK 2 AST-Gram Negative Imipenem (</=0.25->= 16 ug/mL)bioMerieux, Inc.20191
+3K193572VITEK 2 AST-Gram Negative Imipenem/Relebactam (<=0.25/4 - >=16/4 µg/mL)bioMerieux, Inc.2020—
+4K211136VITEK 2 AST-Gram Negative Imipenem/Relebactam (<0.25/4 - >16/4 ug/ML)bioMerieux, Inc.20211
+1K163006VITEK 2 AST-GN Tigecycline (<0.5->8 ug/mL)bioMerieux, Inc.2017—

Descendants by year cleared

Year clearedDevicesWith a Class I recall
201720
201910
202010
202110
FIG. 1 — Lineage of K161227, 2003–2021Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in LON? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new LON device

  1. #1 K260619 VITEK 2 AST-Streptococcus Cefepime (<=0.06 –…score 13.3 · 5 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K121546Vitek 2 Gram Negative Doxycycline
Summary page 5
…Product Code LON Common Name: VITEK® 2 AST-GN Cefepime C. Predicate Device: VITEK® 2 GN Doxycycline (K121546) D. 510(k) Summary: VITEK® 2 AST-Gram Negative Cefepime is designed for antimicrobial susceptibility testing of Gram Negative…
bioMerieux, Inc.2012—

Also cleared against K121546: 6 other devices →

What descends from it? (5)

2 later devices cite it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K172731VITEK 2 AST-GN Amikacin (<=1 ->=64 ug/mL)bioMerieux, Inc.20173
K163006VITEK 2 AST-GN Tigecycline (<0.5->8 ug/mL)bioMerieux, Inc.20170

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 13 years and passes through 1 company; a new generation was cleared every 1.5 years on median.
  • 1 of the 7 ancestors has a recall of any class.
  • Of its descendants, K172731 (bioMerieux, Inc., 2017) has gone furthest, with 3 descendants of its own.
  • 6 other devices also cite its predicate K121546.

How does its category compare?

All LON devices

LON System, Test, Automated, Antimicrobial Susceptibility, Short Incubation: FDA decisions, review times, recalls and adverse event reports over 20 years. 2016, this device’s year, is highlighted.

FDA decisions per year · LON

5in 2025

2007: 192008: 72009: 82010: 12011: 82012: 102013: 72014: 42016: 32017: 102018: 42019: 82020: 52021: 52022: 82023: 112024: 22025: 52026 (partial year): 4
2007high 19 (2007) · low 0 (2015)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · LON

90in 2025

2007: 50 days median2008: 66 days median2009: 76 days median2011: 85 days median2012: 200 days median2013: 115 days median2014: 90 days median2016: 242 days median2017: 89 days median2018: 88 days median2019: 84 days median2020: 81 days median2021: 268 days median2022: 189 days median2023: 210 days median2025: 90 days median2026 (partial year): 146 days median
2007high 268 (2021) · low 50 (2007)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · LON

1in 2025

2008: 12010: 1162011: 32012: 32014: 2, 2 Class I2016: 22017: 12018: 62019: 12020: 82022: 152024: 12025: 12026 (partial year): 6
2007high 116 (2010) · low 0 (2007)2026

Class I (2 since 2007) Class II/III not classified

Adverse event reports per year · LON

690in 2025

2007: 32008: 12010: 32011: 42012: 92013: 32014: 102015: 412016: 942017: 1972018: 5122019: 3152020: 2182021: 2322022: 1802023: 4532024: 4182025: 690
2007high 690 (2025) · low 0 (2009)2025

MAUDE reports naming product code LON, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
2007195003
200876611
200987600
20101—1163
201188534
20121020039
2013711503
20144902 (2)10
20150—041
20163242294
201710891197
20184886512
20198841315
20205818218
202152680232
2022818915180
2023112100453
20242—1418
20255901690
202641466—

What is it indicated for?

VITEK® 2 AST-Gram Negative Cefepime is designed for antimicrobial susceptibility testing of Gram negative bacilli and is intended for use with the VITEK® 2 and VITEK® 2 Compact Systems as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents. VITEK® 2 AST-Gram Negative Cefepime is a quantitative test. Cefepime has been shown to be active against most strains of the microorganisms listed below, according to the FDA label…

Read the full statement (169 words)

VITEK® 2 AST-Gram Negative Cefepime is designed for antimicrobial susceptibility testing of Gram negative bacilli and is intended for use with the VITEK® 2 and VITEK® 2 Compact Systems as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents. VITEK® 2 AST-Gram Negative Cefepime is a quantitative test. Cefepime has been shown to be active against most strains of the microorganisms listed below, according to the FDA label for this antimicrobial.

Active in vitro and in clinical infections:

Enterobacter spp.

Escherichia coli

Klebsiella pneumoniae

Proteus mirabilis

Pseudomonas aeruginosa

In vitro data available but clinical significance is unknown:

Citrobacter koseri (formerly Citrobacter diversus)

Citrobacter freundii

Pantoea agglomerans (formerly Enterobacter agglomerans)

Klebsiella oxytoca

Proteus vulgaris

Providencia rettgeri

Providencia stuartii

Serratia marcescens

The VITEK® 2 Antimicrobial Susceptibility Test (AST) is intended to be used with the VITEK® 2 Systems for the automated quantitative or qualitative susceptibility testing of isolated colonies for the most clinically significant aerobic gram-negative bacilli, Staphylococcus spp., Enterococcus spp., Streptococcus spp. and clinically significant yeast.

Indications for use as stated in the FDA summary.

Also cleared against K121546

6 other devices cite the same predicate.

  • K162737VITEK 2 AST-GN Ciprofloxacin (<=0.06->=4µg/mL)bioMerieux, Inc. · 2017
  • K163637BD Phoenix Automated Microbiology System - GN Ceftazidime/avibactam (0.25/4- 32/4ug/mL)Becton Dickinson & Company · 2017
  • K163563VITEK 2 AST-GN Gentamicin (<=1 – >=16 µg/mL)bioMerieux, Inc. · 2017
  • K161510VTEK 2 AST-GN Ceftolozane/Tazobactam (<=0.25 - >= 32 mcg/mL)bioMerieux, Inc. · 2017
  • K161217VITEK 2 Gram Negative Ceftriaxone (<=0.25->=64 ug/mL)bioMerieux, Inc. · 20171 Class I recall
  • K152075VITEK 2 AST-Gram Negative Ertapenem (<=0.12 - >=8 ug/mL)bioMerieux, Inc. · 20161 recall

More from bioMerieux, Inc.

281 FDA decisions under this applicant name. See the company

  • K260283VITEK 2 AST-Streptococcus Meropenem (=0.06 - =4 µg/mL)bioMerieux, Inc. · 2026
  • K260160VITEK REVEAL GN AST Assay and VITEK REVEAL AST SystembioMerieux, Inc. · 2026
  • K260282VITEK 2 AST-Streptococcus Inducible Clindamycin ResistancebioMerieux, Inc. · 2026
  • K251579VITEK 2 AST-Gram Negative Cefazolin (=<1-=>32 µg/mL)bioMerieux, Inc. · 2025
  • K234012Vitek Compact ProbioMerieux, Inc. · 2025

Recent decisions in LON

The LON category page

  • K260283VITEK 2 AST-Streptococcus Meropenem (=0.06 - =4 µg/mL)bioMerieux, Inc. · 2026
  • K260619VITEK 2 AST-Streptococcus Cefepime (<=0.06 – >=4 µg/mL)Biomérieux, Inc. · 2026
  • K260282VITEK 2 AST-Streptococcus Inducible Clindamycin ResistancebioMerieux, Inc. · 2026
  • K260281VITEK 2 AST-Streptococcus Cefuroxime (<=0.125 - >=8 µg/mL)Biomerieux · 2026
  • K251579VITEK 2 AST-Gram Negative Cefazolin (=<1-=>32 µg/mL)bioMerieux, Inc. · 2025

https://510kreport.com/device/K161227 · printed Nov 6, 2026

Cite this page

510(k) Report. “K161227: VITEK 2 AST-GN Cefepime (<=0.12->=32 ug/mL).” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K161227

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026